Mateon Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development investigational drugs for the treatment of orphan oncology indications. Its product pipeline includes CA4P and OXi4503. The company was founded in 1988 and is headquartered in Agoura Hills, CA.
Company profile
Ticker
OTLC
Exchange
Website
CEO
Vuong Trieu
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
MATEON THERAPEUTICS INC, OXIGENE INC
SEC CIK
Corporate docs
IRS number
133679168
OTLC stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
23 Apr 24
POS AM
Prospectus update (post-effective amendment)
18 Apr 24
POS AM
Prospectus update (post-effective amendment)
12 Apr 24
10-K
2023 FY
Annual report
12 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Entry into a Material Definitive Agreement
2 Feb 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Entry into a Material Definitive Agreement
30 Oct 23
8-K
Regulation FD Disclosure
23 Aug 23
10-Q
2023 Q2
Quarterly report
18 Aug 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 20.00 k | 20.00 k | 20.00 k | 20.00 k | 20.00 k | 20.00 k |
Cash burn (monthly) | (no burn) | 21.16 k | (no burn) | 924.77 k | 82.95 k | 85.76 k |
Cash used (since last report) | n/a | 145.61 k | n/a | 6.36 mm | 570.89 k | 590.23 k |
Cash remaining | n/a | -125.61 k | n/a | -6.34 mm | -550.89 k | -570.23 k |
Runway (months of cash) | n/a | -5.9 | n/a | -6.9 | -6.6 | -6.6 |
Institutional ownership, Q4 2020
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Jun 23 | Trieu Vuong | Common Stock | Buy | Acquire P | No | No | 0.021 | 425,000 | 8.93 k | 92,044,217 |
28 Jun 23 | Trieu Vuong | Common Stock | Buy | Acquire P | No | No | 0.026 | 75,000 | 1.95 k | 91,619,217 |
16 Jun 23 | Trieu Vuong | Common Stock | Buy | Acquire P | No | No | 0.026 | 100,000 | 2.60 k | 91,544,217 |
14 Jun 23 | Trieu Vuong | Common Stock | Buy | Acquire P | No | No | 0.0326 | 400,000 | 13.04 k | 91,444,217 |
26 May 23 | Trieu Vuong | Common Stock | Buy | Acquire P | No | No | 0.0341 | 126,888 | 4.33 k | 91,044,217 |
2 May 23 | Trieu Vuong | Common Stock | Buy | Acquire P | No | No | 0.045 | 100,000 | 4.50 k | 90,917,329 |
Press releases
With Rise In Pancreatic Cancer, Oncotelic Therapeutics (OTCQB: OTLC) Opens Up Enrollment For STOP-PC Clinical Trial
10 Apr 24
Linkage of Cancer and Lupus in Gliomas Patients
25 Mar 24
Invitation to Participate in STOP-PC Clinical Trial
4 Mar 24
Oncotelic Therapeutics Shares Groundbreaking Discovery In Pediatric Brainstem Tumors Demonstrating Potential For New Cancer Immunotherapy Treatments
21 Feb 24